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Introduction 
INTRODUCTION 
Induction of labor implies the artificial initiation of uterine contractions prior 
to their spontaneous onset beyond the period of viability. Induction of labor is 
indicated when the benefits of termination of pregnancy to the mother or the fetus 
outweighs those of continuing pregnancy. Labor induction is a clinical intervention 
that has the potential to confer major benefits to the mother and newborn. 
The history of labor induction dates back to Hippocrates' original descriptions 
of mammary stimulation and mechanical dilation of the cervical canal 1. During the 
second century AD, Soranus practiced a combination of procedures to induce labor, 
including artificial rupture of the membranes. Other labor induction methods were 
introduced during this period; Moshion was the first to describe manual dilation of the 
cervix, and Casis invented several instruments capable of cervical dilation. 
Midway through the 16th century, Paré devised a technique that combined 
manual cervical dilation and internal podalic version in patients with uterine 
hemorrhage 2. Bourgeois, a disciple of Paré, continued this practice and also induced 
and augmented labor with strong enemas and mixtures of several folk medicines 3  
From the 2nd through the 17th centuries, mechanical methods to induce labor 
came into more common use. In 1756, at a meeting held in London, physicians 
discussed the efficacy and ethics of early delivery by rupturing the membranes to 
induce labor 4. 
In 1810, James was the first in the United States to utilize amniotomy to 
induce premature labor 5. Amniotomy and other mechanical methods remained the 
methods of labor induction most commonly employed until the 20th century. 
In 1906, Dale observed that extracts from the infundibular lobe of the pituitary 
gland caused myometrial contractions 6.Three years later; Bell reported the first 
experience with use of a pituitary extract for labor induction 7.With the introduction of 
pituitary extract as a hormonal method of labor induction in 1913, the use of this 
method gained acceptance among obstetricians. However, due to the use of large 
doses and the impurity of the extract, numerous adverse effects were reported. 
Gradually, as the number of reported cases of uterine rupture increased, pituitary 
extract became discredited in many centers. 
Initially, oxytocin (pituitary extract) was administered via intramuscular or 
subcutaneous routes. In 1943, Page suggested that the pituitary extract oxytocin be 
given in the form of an intravenous infusion 8 and in 1949; Theobald reported his 
initial results with this form of administration 9. Fourteen years later in 1953, the 
structural formula of oxytocin was discovered, and synthetic oxytocin has been in use 
since 1955. 
In 1968, Karim and colleagues were the first to report the use of 
prostaglandins for labor induction 10. Since then, the use of prostaglandins, in 
different varieties and forms of administration, has become a common method of 
labor induction 11. More recently, the synthetic prostaglandin analogue misoprostol 
has gained acceptance as an effective and safe method of labor induction 12.  
Induction of labor is common in obstetric practice. According to the most 
current studies, the rate of induction varies from 9.5 to 33.7 percent of all pregnancies 
annually 18. In the absence of a ripe or favorable cervix, a successful vaginal birth is 
less likely.  
The amount of uterine pressure to dilate a ripe cervix is thought to be 
approximately 1600 mm Hg, while the pressure to dilate an unripe cervix is estimated 
to be greater than 5 times that, or 10,000 mm Hg. Therefore, cervical ripening or 
preparedness for induction should be assessed before a regimen is selected. 
Assessment is accomplished by calculating a Bishop score.  
Cervical ripening usually begins prior to the onset of labor contractions and is 
necessary for cervical dilatation and the passage of the fetus. Cervical ripening is the 
result of a series of complex biochemical processes that ends with rearrangement and 
realignment of the collagen molecules. The cervix thins, softens, relaxes, and opens in 
response to uterine contractions, which pull the cervix over the presenting fetal part. 
Cervical ripening is the result of realignment of collagen, degradation of collagen 
cross-linking due to proteolytic enzymes, and dilatation resulting from these processes 
plus uterine contractions. 
The most commonly used methodology to evaluate cervical ripening is the 
Bishop score because it is simple and has the most predictive value. This score uses 
cervical dilatation, effacement, consistency, position, and the station of the presenting 
part 
BISHOP SCORE 
Bishop Scoring System 27
Factors 
Score 
Dilation 
(cm) 
Effacement 
(%) 
Station*
Cervical 
Consistency 
Position of 
Cervix 
0 Closed 0-30 -3 Firm Posterior 
1 1-2 40-50 -2 Medium Mid position 
2 3-4 60-70 -1,0 Soft Anterior 
3 5-6 80 +1,+2 -- -- 
*Station reflects a. 3 to +3 scale. 
Modified from Bishop EH. Pelvic scoring for elective induction. Obstet Gynecol 
1964;24:267 
A Bishop score of 6 or more is considered significant for cervical ripening and 
favorable for induction of labor. 
When the Bishop score is less than 6, it is recommended that a cervical 
ripening agent be used before labor induction 63.  
Numerous  pharmacological and non pharmacological methods of labor 
induction are available .Non pharmacologic approaches to cervical ripening and labor 
induction have included herbal compounds, castor oil, hot baths, enemas, sexual 
intercourse, breast stimulation, acupuncture, acupressure, transcutaneous nerve 
stimulation, and mechanical and surgical modalities. Of these non pharmacologic 
methods, only the mechanical and surgical methods have proven efficacy for cervical 
ripening or induction of labor 18.  
Pharmacologic agents available for cervical ripening and labor induction 
include prostaglandins, misoprostol, mifepristone, and relaxin. When the Bishop score 
is favorable, the preferred pharmacologic agent is oxytocin. 
In the current standard of care PGE2 gel is routinely used as an induction 
agent. This is a currently accepted standard of care. Its efficacy and safety as an 
induction agent has been proven by many studies. Even though it is a standard means 
of care in labor induction, common problems encountered in day to day practice in 
applying this induction agent like 
Patient needs to be admitted  
Drug application (intracervically) is cumbersome to the patient 
Needs the availability of an expert 
If there is an orally available induction agent which can be administered orally 
the above mentioned problems can be easily overcome. This gains importance in day 
to day practice especially in obstetrics departments where admissions can be 
minimized especially where there is an increased need for pressure of beds. If an oral 
induction agent is available the patient assessment can be made in OPD and induction 
can be made as an op procedure and the patient can be asked to get admitted after 
allowing sufficient time for cervical ripening and effacement.  
This practice is well implemented in western countries and requires the 
necessity to be implemented in our country also put forth. This is also convenient to 
the patient as the hospital stay is considerably reduced. The search for this kind of 
induction agent has been going on for a considerable period of time and various 
induction agents like misoprostol have been tried so far. 
MIFEPRISTONE 
 
IUPAC name  
11β-[p-(Dimethylamino) phenyl]-17β-hydroxy-17-(1-propynyl) estra-4, 9-dien-3-
one 
Mifepristone blocks the effect of progesterone by acting on the progesterone 
receptors. Progesterone is necessary for the establishment and maintenance of 
pregnancy in women. It also causes relaxation of the myometrium and leads to the 
prevention of myometrial contraction. With its anti progesterone effects, mifepristone 
prevents progesterone from exerting its action. It also blocks receptors for other 
steroids, including androgens and also increases the production of prostaglandins by 
the uterine lining during pregnancy. The blockade of progesterone effects and the 
stimulation of prostaglandins increase uterine contractility. Blood levels of 
mifepristone peak within 2 hours after oral dosage, decreases by half over 20 hours, 
and are excreted mainly in bile.  
In late pregnancy, the uterus is sensitized by mifepristone to prostaglandins 
and promotes cervical dilatation which induces labor. p receptors in the placenta are 
also blocked by mifepristone effectively, resulting in the termination of pregnancy. 
Thus, Mifepristone appears to be efficacious, safe and adds valuable alternatives to 
the cervical ripening and labor induction 
  
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature  
REVIEW OF LITERATURE 
The Cochrane based review of mifepristone in Cochrane database 2009 30 says 
the female steroid sex hormone, progesterone, inhibits contractility of the uterus. A 
new class of pharmacological agents (anti progestin) has been developed to 
antagonize the action of progesterone. Of these mifepristone also called as RU486 is 
best known. Mifepristone, a 19 nor steroid which has greater affinity for progesterone 
receptors than does progesterone itself. It thus blocks the action of progesterone at the 
cellular level. The pharmacokinetics of mifepristone is characterized by rapid 
absorption and a long half life of 25 to 30 hours (Heikinheimo 1997) 26. Key 
metabolites also have high affinity to progesterone receptors  
Mifepristone now has an established role in termination of pregnancy (in 
combination with prostaglandins) during the early first, and the second trimesters 
(Van look 1995)34. Mifepristone is also being investigated as a possible contraceptive 
agent. 
Mifepristone has potential also as a method of inducing labor in late 
pregnancy, through its actions in antagonizing progesterone, and thus increasing 
uterine contractility. Mifepristone has been shown to induce labor in rats (FANG 
1997) 43, through opposition to progesterone – induced suppression of oxytocin 
receptors, and enhanced synthesis of prostaglandins. Mifepristone has also been 
shown to induce preterm birth in mice, associated with a rise in prostaglandins and 
cytokines (Dudley 1996) 42 
A randomized controlled trial in beef heifers found a mean time to delivery of 
43 hours after mifepristone administration, compared to 182 hours in placebo treated 
controls (Dlamini 1995); interestingly, retained placenta was a problem in the 
experimental group. In a primate model (the macaque), mifepristone administration 
induced prostaglandin F2 alpha production by decidua, but not prostaglandin E2 
production by amnion (haluska 1994) 26 
There is thus, reason to anticipate from animal studies and termination studies 
in human pregnancies that mifepristone might prove an effective method of inducing 
labor in late human pregnancy. 
In 2000, Wing DA et al 29 in their study reported that 54 percent normal 
women given 200 mg Mifepristone daily for two consecutive days went into labor 
within 72 hours compared with only 18.2 percent of those given a placebo.   
A prospective study done by McGill J et al United kingdom 2007 16 showed 
that the rate of caesarean section was significantly lower among women induced with 
mifepristone alone. Another study from Sweden, department of women and child 
health says that the median time taken from the onset of treatment unto delivery is 
relatively lower in groups with mifepristone than the control group.  
A study from France, department of obstetrics and gynecology, Clamart 15 
says that mifepristone appears safe and useful with no adverse effects on the fetus or 
the mother. Another study by Michel J Fassett et al from Los angles, California, USA 
29 says that oral mifepristone administration to women with pregnancies beyond 41 
weeks increases uterine activity in the absence of externally administered uterotonic 
agents. A similar study from USA says Mifepristone is proved effective for cervical 
ripening and reduced the time to delivery compared with placebo. 
A randomized controlled study, by Berkane and associates in 2005 28 on the 
effectiveness of mifepristone for ripening the cervix and inducing labor in term 
pregnancies among 346 women stated that mifepristone was well tolerated by the 
mother and fetus without any adverse outcomes. 
A randomized double-blind trial by Frydman et al 13 employing 200 mg of 
mifepristone daily for 2 days resulted in a shorter interval to the onset of labor, and 
less oxytocin was required for those achieving vaginal delivery. In the mifepristone 
group, 58% went into spontaneous labor, compared with 22.6% in the placebo group. 
Elliot 14 and colleagues compared the effects of 50 mg and 200 mg of oral 
mifepristone with placebo on cervical ripening and labor induction in primigravid 
women with unfavorable cervices at term. At a dose of 200 mg, mifepristone resulted 
in a favorable cervix or spontaneous labor more often than did placebo. Another 
randomized control trial by Giacalone 22 et al from France also proved that 
mifepristone is effective for cervical ripening and reduced the time to delivery when 
compared with placebo 
A retrospective study by Gallot 14 et al from France compared the mode of 
delivery in two groups where labor was induced with mifepristone .It concluded that 
mifepristone was successful in inducing labor spontaneously in over 50% of 
pregnancies after 41 weeks of gestation. 
A randomized control trial done by Wing DA 29et al in university of south 
California among 180 antenatal women for preinduction cervical ripening beyond 41 
weeks of gestation said that mifepristone had a modest effect on cervical ripening 
when given 24 hours before labor induction, appearing to reduce the need for 
misoprostol and oxytocin compared with placebo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim & Objective 
AIM OF THE STUDY 
 To compare the effect of oral mifepristone as a pre induction cervical ripening 
agent at term gestation age in normal and uncomplicated pregnancies when 
compared to vaginal prostaglandin E2  
 To compare improvement of bishop score following induction 
 To compare the induction delivery time interval  
 To compare the maternal and fetal outcomes 
 To compare the rate of fetal distress following delivery 
  
 
 
 
 
Materials & Methodology 
 MATERIALS AND METHODS 
All term antenatal patients who are coming for checkup / delivery in PSG 
Hospitals – Labor ward were included in the study. The study was a prospective case 
control study with one hundred and twenty women was included in the study from 
June 2009 to December 2010.    
SELECTION CRITERIA 
Antenatal women between 37 completed weeks of gestation upto 42 weeks of 
gestation with singleton pregnancies and cephalic presentation, with an unripe cervix 
(Bishop Score </= 4) with no medical complications warranting immediate delivery.  
INCLUSION CRITERIA 
o Term gestational age 
o Reactive fetal heart rate pattern 
o Pre induction bishop score < 4 
EXCLUSION CRITERIA 
o Premature rupture of membranes 
o Oligohydramnios 
o Multiple pregnancies 
o Medical complications of pregnancy where delivery is urgent 
o Previous LSCS 
o Post term pregnancy 
 METHODOLOGY 
The antenatal patient comes to labor ward where a basic assessment for risk 
factors is made and if the patient fits into the criteria of uncomplicated term gestation 
with bishop score of < 4 then she is entered into the study and the researcher is 
informed. The researcher after verifying the inclusion and exclusion criteria confirms 
inclusion of the patient into the study. The patients were randomly allocated (by 
sealed envelope method) into study group and control group. 
STUDY GROUP 
In the study group following a basic pelvic assessment (to rule out 
cephalopelvic disproportion) and reactive Non stress test - bishop score is assessed. If 
the score is < 4 (unfavorable cervix) pre induction cervical ripening done with oral 
T.Mifepristone 200mg stat. The patient is under observation for the spontaneous onset 
of labor or draining PV or reassessed after 48 hours – whichever is earlier. Labor was 
defined by effective uterine contractions with gradual cervical modifications. 
Those patients who did not go into labor were reassessed after 48 hours. A 
post induction bishop score of > 6 is favorable and says that the induction agent is 
successful. The method of further induction is decided and implemented according to 
the Bishop score.  
CONTROL GROUP 
In the control group following a basic pelvic assessment (to rule out 
cephalopelvic disproportion) and a Non stress test is done and Bishop score is 
assessed. If the score is < 4 (unfavorable cervix) and NST is reactive PGE2 gel is 
 applied intracervically. The patient is reassessed after spontaneous onset of labor or 
draining PV or after 12 hours – whichever is earliest. A post induction bishop score of 
> 6 is favorable and says that the induction agent is successful. The method of further 
induction is decided and implemented according to Bishop score. 
In the interval period fetal heart rate monitoring is done to assess the fetal well 
being. 
Abnormal FHR patterns were defined as the presence of fetal tachycardia or 
bradycardia, late decelerations or moderate to severe FHR decelerations. 
The pre and post induction assessment will be made by equally skilled 
assessors of the same designation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results & Analysis 
 RESULTS AND ANALYSIS 
In our study all term antenatal patients who were booked at PSG Hospitals or 
unbooked were included in the study. The study was a prospective case control study 
with one hundred and twenty women included in the study from June 2009 to 
December 2010. 
Women with previous caesarean births, post term pregnancies, PROM and 
medical complications warranting immediate delivery were excluded from the study.   
This clinical study with 60 patients in the study group and 60 in the control 
group was undertaken to study the Assessment of bishop score, mean duration of 
labor induction, efficacy for cervical ripening and as an induction agent, rate of 
vaginal deliveries, incidence of fetal distress, rate of caesarean section and their 
indication and rate of NICU admission. 
Statistical data analysis was calculated using SPSS software  
 ANALYSIS 
TABLE 1 
AGE DISTRIBUTION OF PATIENTS IN TWO GROUPS 
Age in years 
Study Group Control group 
No % No % 
18-20 14 23.3 10 16.7 
21-25 24 40.0 29 48.3 
26-30 14 23.3 19 31.7 
>30 8 13.3 2 3.3 
Total 60 100.0 60 100.0 
Mean ± SD 24.75±4.17 24.07±3.08 
Samples are age matched with p=0.309 
The age differences are similar and comparable in the study and control group 
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Fig 1. AGE DISTRIBUTION OF PATIENTS IN TWO GROUPS
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 TABLE 2 
GESTATIONAL AGE IN WEEKS 
Gestational age 
in weeks 
Study Group Control group 
No % No % 
37 9 15.0 5 8.3 
38 18 30.0 21 35.0 
39 19 31.7 15 25.0 
40 & above 14 23.3 18 30.0 
Total 60 100.0 60 100.0 
Mean ± SD 38.65±1.04 38.78±0.98 
p=0.486 
The Gestational age is statistically similar between two groups  
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 TABLE 3 
PARITY STATUS OF PATIENTS IN TWO GROUPS  
 
Study Group Control group 
No % No % 
Nullipara 48 80 44 73.3 
Para 1 11 18.3 16 26.6 
Para > 1 1 1.6 - - 
Total 60 100.0 60 100.0
The parity status was comparable in both groups 
 Fig 3. PARITY STATUS
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 TABLE 4 
COMPARISON OF PRE INDUCTION BISHOP SCORE 
Pre-induction Bishop 
score 
Study Group 
(n=60) 
Control group 
(n=60) 
No % No % 
0 12 20.0 25 41.7 
1 26 43.3 10 16.7 
2 13 21.7 19 31.7 
3 9 15.0 6 10.0 
Mean ± SD 1.32±0.97 1.10±1.07 
The pre induction Bishop score was comparable in both groups 
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 TABLE 5 
FAVORABLE IMPROVEMENT IN BISHOP SCORE (6 and more) 
 No (n=60) % P value 
Study group 46 76.6 χ2=30.00; 
P<0.001**Control group 16 26.6 
The favorable improvement in Bishop Score was more in the mifepristone 
treated group when compared with the prostaglandin E2 group 
Of the 46 patients - 28 patients had Bishop score 6 during reassessment 
 Fig 6. FAVORABLE IMPROVEMENT IN BISHOP SCORE (6 and more)
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 TABLE 6 
COMPARISON OF FAVOURABLE IMPROVEMENT IN BISHOP SCORE - 
NULLIPARA VS PAROUS WOMEN 
 
Nullipara Parous women 
No % No % 
Study group 39 81.2 7 58.3 
Control group 6 13.6 10 62.5 
Inference χ2=13.30; P<0.001** 
The favorable improvement in bishop score is more in nullipara when 
compared to parous women (P<0.001) 
In the control group the patients with unfavorable cervix required a second or 
third dose of PG E2 
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 TABLE 7 
COMPARISON OF MODE OF DELIVERY 
Mode of delivery 
Study Group 
(n=60) 
Control 
group 
(n=60) 
No % No % 
NVD 20 33.3 14 23.3
VACCUM 20 33.3 16 26.6
FORCEPS ASSISTED 3 5.0 2 3.3 
LSCS 17 28.3 28 46.6
Incidence of LSCS is more in control group  
(Not statistically significant P= 0.219) 
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 TABLE 8 
INDICATION FOR LSCS 
 
Study Group 
(n=17) 
Control 
group 
(n=28) 
No % No % 
Fetal distress 7 41.1 14 50 
Non progression 7 41.1 12 42.8 
Meconium stained 2 11 2 7.1 
Tight cord ar.neck 1 5.9 0 0 
Total 17 100.0 28 100.0
The rate of fetal distress and meconium stained liquor is comparable in 
both groups 
6 infants in the mifepristone group and 4 in the PG E2 group had meconium in 
utero of which 2 from each group had to be taken up for LSCS 
 Fig 9. INDICATION FOR LSCS
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 TABLE 9 
COMPARISON OF BIRTH WEIGHT OF BABIES 
Birth weight 
(kg) 
Study Group 
(n=60) 
Control group 
(n=60) 
No % No % 
<2.50 9 15.0 9 15.0
2.50-3.00 26 43.3 21 35.0
3.0-3.50 19 31.7 24 40.0
3.50 & above 6 10.0 6 10.0
Mean ± SD 2.93±0.38 2.94±0.39 
Birth weight (kg) is statistically similar between two groups with p=0.842 
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 TABLE 10 
COMPARISON OF FETAL DISTRESS, NICU ADMISSION AND 
VENTILATOR SUPPORT 
 
Study Group 
(n=60) 
Control group 
(n=60) P value 
No % No % 
Fetal distress 4 6.7 5 8.3 0.729 
NICU admission 2 3.3 1 1.6 0.496 
Ventilator support 0 0.0 0 0.0 1.000 
The incidence of fetal distress and NICU admission was comparable in 
both groups 
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 TABLE 11 
COMPARISON OF TREATMENT DELIVERY TIME INTERVAL 
Delivery Interval 
Time 
Study Group 
(n=60) 
Control group 
(n=60) 
No % No % 
1-30 7 11.7 21 35.0 
31-50 17 28.3 36 60.0 
51-70 34 56.7 3 5.0 
>70 2 3.3 0 0.0 
Mean ± SD 50.74±15.29 35.47±8.39 
Treatment delivery interval time is significantly more in Study group 
compared to Control group with p<0.001 
This can be explained due to the prolonged t (1/2) of mifepristone 
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 TABLE 12 
AUGMENTATION WITH OTHER DRUGS 
 No (60) % 
Study group 39 65.0 
Control group 46 76.6 
Inference χ2=1.98; P=0.160 
There was no difference in the need for augmentation with other drugs in 
both groups (P not significant) 
 Fig 13. AUGMENTATION WITH OTHER DRUGS
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Discussion 
 
 DISCUSSION 
The process of labor initiation remains a mystery. It is well known, however, 
that progesterone is integral in the maintenance of pregnancy. It is hypothesized that 
anti progestin exposure in pregnancy will enhance the initiation of parturition.  
Mifepristone a progesterone antagonist is a steroid compound which may 
soften the cervix and cause uterine contractions. This medication has been shown to 
be effective for elective abortions and medical termination of pregnancy during the 
first trimester. This lead others to study the effect of mifepristone in term pregnancies. 
Results of these studies hav 
.0e demonstrated that mifepristone may ripen the cervix and induce labor 
while not increasing the risk to the fetus. 
In this study, study population comprised of 120 patients with equal no of 
patients in the study and control group. There were no significant statistical 
differences between the treatment groups in demographics or medical or obstetrics 
history.  
92 (76.6%) patients were nulliparous, 27 (22.5%) were para 1 (delivered once) 
and 1 (0.83%) para >1 (delivered more than once). The mean gestational age at 
treatment initiation was 38.6 in the study group and 38.7 in the control group, with no 
significant difference across the groups.  
The mean bishop score at inclusion was 1.32 in the study group and 1.10 in 
the control group with no significant differences between the groups. The bishop 
score was < 2 in 73 patients and > 2 in 47 patients. 
 The success rate was higher when the Bishop score at inclusion was 3 or 4 (P 
<0.0001). A study done by Elliot 64 and colleagues compared the effects of 50 mg and 
200 mg of oral mifepristone with placebo on cervical ripening and labor induction in 
primigravid women with unfavorable cervices at term. At a dose of 200 mg, 
mifepristone resulted in a favorable cervix or spontaneous labor more often than did 
placebo. 
Treatment was successful (onset of labor and/or a bishop score >/= 6 before or 
at the time of reassessment for study and control group) in 46 (76.6%) women in 
study group when compared to 16 (26.6%) women in the control group. 
There are many studies comparing mifepristone with placebo. 
A similar comparison was observed in a study by Wing DA 29 et al who 
reported that 54 percent normal women given 200 mg Mifepristone daily for two 
consecutive days went into labor within 72 hours compared with only 18.2 percent of 
those given a placebo. 
In a RCT study done by Berkane 28 et al which compared mifepristone with 
placebo showed that treatment was successful in about 52.7% of the patients 
assessable for efficacy with no significant difference among the groups (P=0.73). 
A study done by Karl et al stated that mifepristone treated group was 
successful in 52.7% of patients when compared with placebo. Another randomized 
control trial by Giacalone 22 et al from France also proved that mifepristone is 
effective for cervical ripening and reduced the time to delivery when compared with 
placebo. 
 39 (81.2%) nulliparous women had favorable improvement in bishop score 
when compared to 6 (13.6%) parous women. A study done by Nadia 28 et al showed 
that the relationship between parity and success rate was close to significance (P = 
0.053). 
The mean treatment to delivery interval was 50.7 hours in the mifepristone 
treated group when compared to 35.46 hours in the prostaglandin treated group. The 
difference in the two groups was nearly 15 hours, which is in part due to the 48 hour 
observation period after mifepristone administration. 
A Cochrane review 2009 30 said that compared to placebo mifepristone treated 
women were less likely to have an unfavorable cervix at 48 hours (RR – 0.39) or at 96 
hours (RR- 0.39). Further the review stated that mifepristone treated women were 
more likely have delivery within 48 and 96 hours of treatment than with the placebo 
treated group. 
A study done by Frydman13 et al said that the mean interval between the time 
of induction and the onset of labor was significantly shorter in the mifepristone 
treated group.  
A study done by Berkane 28 et al showed that as the dose of mifepristone 
increased the interval between the treatment and onset of labor, and between the 
treatment and delivery tended to be shorter. The difference was significant between 
600mg mifepristone and placebo  
A study done by Karl et al stated that labor was prolonged in the groups who 
received lower doses of mifepristone than those who received 400 or 600 mg. A study 
 done by Josie 62 et al stated that women treated with mifepristone are more likely to 
have a favorable cervix within 48 to 96 hours when compared with placebo. 
Another study by Zhonghua et al from Beijing stated that the cervical ripening 
ratio was 100% in the mifepristone treated group. 
Another study from Sweden 14, department of women and child health says 
that the median time taken from the onset unto delivery is relatively lower in groups 
with mifepristone than the control group.A similar French study 15 stated that the 
onset of labor was one day earlier in the mifepristone treated group when compared 
with placebo. 
The rate of normal and assisted vaginal deliveries was 66.6% in the 
mifepristone treated group when compared to 49.9% in the prostaglandin treated 
group with a significant P value. A similar comparison was observed by an RCT by 
Wing et al 29 who stated that 87.5% women in the mifepristone treated group were 
delivered vaginally 48 hours after the start of treatment than 70% in the placebo 
treated group. 
Another study by Zhonghua et al from Beijing stated that the incidence of 
vaginal delivery was 80.8% in the mifepristone treated group. 
The rate of caesarean deliveries (28.3%) was comparably less in the 
mifepristone treated group than the prostaglandin treated group (46.6%).  
A Cochrane review 30 in 2009 said that the mifepristone treated women were 
less to undergo caesarean section (RR -0.71). Another prospective study done by Mc 
 gill 16 et al United Kingdom showed that the rate of caesarean section was 
significantly lower among women induced with mifepristone alone. 
A similar comparison was found in a study by Josie et al who stated that the 
mifepristone treated women were less likely to undergo caesarean section 
Of the 17 (28.3%) mifepristone treated women who underwent caesarean 
section 7 (41%) cases were indicated for fetal distress. 1 (5.8%) case had tight loop of 
cord around the neck. Among the 28 (46.6%) prostaglandin treated women 14 (50%) 
cases were for fetal distress. A similar comparison was observed in a study Wing 29 et 
al with about 60% of cases in the mifepristone treated group was for fetal distress. 
An analysis of the effect of parity on outcomes of induction revealed that a 
mean of 22.8% of nulliparous women delivered vaginally when compared to a mean 
of 50% parous women. This is comparable to the study by Berkane 28 et al which 
stated that the rate of vaginal delivery increases with parity. 
The mean induction delivery time interval for the mifepristone treated 
nulliparous women was 52.8 hours when compared to 36.45 hours in the 
prostaglandin treated nulliparous women. A RCT done by Guberman 28et al said that 
the duration of labor was longer for nulliparous women when compared with the 
parous subjects irrespective of the mode of treatment. 
Meconium passage in utero occurred in 6 (10%) infants of the mifepristone 
treated group which is more when compared to 4 (6.6%) infants in the prostaglandin 
treated group which is similar to a study by Wing 29 et al where meconium passage 
was 9.1% in the mifepristone treated group.  
 Abnormal FHR pattern was found were found in 7 (11.6%) cases of the 
mifepristone treated group and 14 (23%) cases of the prostaglandin treated groups. 
A Cochrane review 30 2009 stated that the rate of abnormal FHR pattern was 
higher in the mifepristone treated group. Another study by Wing 29 et al stated than 
the rate of fetal distress was higher in the mifepristone treated group. 
The birth weight and rate of Apgar score at 1 min and at 5 min was 
statistically similar in the study and control group. Two (3.3%) infants in the study 
group and one (1.6%) infant in the control group required admission in NICU. A 
study by Guberman 28 et al stated that the rate of NICU admission and the need for 
resuscitation was higher in the mifepristone treated group 
A Cochrane review 30 in 2009 said that the incidence of neonatal 
hypoglycemia might be more common after exposure to mifepristone (it antagonizes 
the action of glucocorticoids as well as the action of progesterone).  
Another study done by Karl et al stated that there was no difference in fetal 
tolerability and the rate of fetal distress. A study done by clamart 15 et al from France 
says that mifepristone appears safe and useful with no adverse effects on the fetus or 
mother 
There was no significant difference in the maternal heart rate (beats/min) or 
systolic or diastolic blood pressure on day 0 , day 1 or day 2 of treatment in both the 
study and control group which is comparable to a study by Nadia 28 et al where in 
there was no significant difference. Another study by Wing et al also stated that there 
were no adverse uterine abnormalities or maternal complications observed in the 
mifepristone treated groups. 
 The need for augmentation with other uterotonic agents was less with 
mifepristone treated groups (65%) when compared with the prostaglandin treated 
groups (76.6%) though not statistically significant. 
A RCT done by Frydman 13 et al suggested that the need for oxytocin was 
much lesser in the mifepristone treated group when compared with placebo. Another 
French 15 study stated that women treated with mifepristone had more spontaneous 
labor and lesser doses of augmentation. 
Another study by Wing 29 et al stated that the dose and amount of oxytocin 
required was lesser in the mifepristone treated group 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 CONCLUSION 
Mifepristone has proved very useful for medical abortion in the first and 
second trimester termination of pregnancy. It has an established role as an effective 
cervical priming agent. This effect is now utilized for cervical ripening in term 
pregnancies. Mifepristone is well tolerated by pregnant women and the efficacy which 
has been proved in many trials. 
There are a few reports in the literature describing the effect of mifepristone as 
a pre induction cervical ripening agent for term pregnancies. However available data 
do show that mifepristone is better than a placebo at ripening the cervix or inducing 
labor. 
In our study we compared the effect of mifepristone with prostaglandin E2 
gel. 
In our study we found that mifepristone as a pre induction cervical ripening 
agent had better proven efficacy especially in primigravid women as similarly proved 
by various other earlier standard trials. The need for augmentation with other 
oxytocics was also reduced in the mifepristone treated groups. 
Theoretically, mifepristone has appeal as a method of inducing labor in 
women with previous caesarean section as it does not involve administering 
exogenous oxytocic drugs that have potential to over stimulate. There is evidence of a 
possible reduction in the incidence of caesarean section following mifepristone 
treatment (compared to placebo) that would justify further trials quoted as per the 
reviews of Cochrane 30 2009.   
 This study was a pilot study to assess the efficacy of mifepristone as a pre 
induction cervical ripening agent in term pregnancies and to study its adverse effects 
on mother and fetus. The results are encouraging with no significant adverse effects 
on mother and fetus. Further efforts can be put forth to probe the study further and 
prove the effectiveness of the drug and its efficacy. Further studies can be done 
comparing 200 mg of mifepristone with 400 mg or even higher doses if found 
favorable. It promises to be a more compliant drug in near future. 
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Annexures  
 PSG Institute of Medical Science and Research, Coimbatore 
 
INFORMED CONSENT 
 
I, Dr.P.Uma Devi, MD., (OG) post graduate from the department of Obstetrics 
and Gynaecology of the PSG Institute of Medical Sciences & Research (PSG 
IMS&R), am carrying out a study titled 
 
Is oral mifepristone as effective as vaginal prostaglandin E2 in pre induction cervical 
ripening at term gestation in normal and uncomplicated pregnancies? 
 
Under the aegis of the Department of Obstetrics and Gynaecology, PSG IMSR.  
  
The objectives of this study are: 
To assess the effectiveness of oral mifepristone as a pre induction cervical 
ripening agent in comparison with vaginal prostaglandin E2 gel by assessing the 
favourable improvement in Bishop’s score 
 
This goal of the study is  
To study whether oral mifepristone is as effective as vaginal prostaglandin E2 
gel for pre induction cervical ripening in term viable uncomplicated pregnancies 
 
Sample size: 100.  
Respondents are all term antenatal patients who are coming for checkups/ delivery in 
PSG Hospitals – Labour ward, Coimbatore 
   
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will be 
carrying out Initial interview to assess for the risk factors (if any) for the patient and 
following inclusion of the patient into the study general and systemic examination 
with per vaginal examination for assessment of pre induction bishop score will be 
done. Subsequently non stress test for assessment of foetal well being will be done 
followed by doing repeat per vaginal examination for assessing the favourability of 
bishop score. 
  
If you are uncomfortable in answering any of our questions during the course of the 
interview / blood sample collection, you have the right to withdraw from the 
interview / study at anytime. You will NOT be paid any remuneration for the time 
you spend with us for this interview / study. The information provided by you will be 
kept in strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used 
for approved research purposes only. 
 
 Consent: The above information regarding the study, has been read by me/ read to 
me, and has been explained to me by the investigators from the PSG IMS&R. Having 
understood the same, I hereby give my consent to them to interview me. I affixing my 
signature / left thumb impression to indicate my consent and willingness to cooperate 
in this study. 
 
 
Respondent ID: _________.    Signature / Left thumb impression of the 
Respondent.         Signature of the Investigator with date 
 
      
 
 
     Signature of the witness 
 CASE PROFORMA 
 
Name     Age  Hospital no    
 
LMP   EDD 
Gestational age 
DOA   DOD 
 
Obstetric formula 
 
Chief complaints 
 Pain  + / -   
 Bleeding PV  + / - 
Leaking PV + / - 
 
Foetal movments 
 Yes / no 
 
Menstrual H/o 
 Days -  
 Cycles – regular / irregular 
 
Marital H/o 
 Married since 
 
Booked / unbooked 
 
Antenatal complications 
 PIH /GDM / IUGR / preterm / anaemia / oligohydramnios/ previous LSCS - 
ind 
 
Past H/o 
  Hypertension / DM / BA / PTB 
 
Examination 
 General examination 
  Pallor   no / mild / severe  
Edema  + / - 
Breast  normal / abnormal  
Thyroid palpable / not palpable 
Height   weight  
Pulse rate   Blood pressure 
 
 Systemic examination 
  CVS  
  RS 
  P/A – Height of uterus 
            Lie / presentation 
            Presenting part  
            Engaged / unengaged 
 
FHR   
NST 
 
P/S – leaking + / -  ; if (+) colour  
P/V – cervix – Consistency 
  Position  
  Effacement 
  Membrane status 
  Station 
 
Bishop score (before induction) 
 
Investigations  
 Hb 
 RBS 
 Urine routine 
Blood grouping 
HIV 
HbsAg 
 
USG  
   GA by LMP / USG 
   EFW 
   AFI 
   Presentation 
 
Labour 
 Spontaneous 
 Induction – following induction daily NST monitoring and 4th hourly FHR 
monitoring is essential 
 Induced with  
  1. PGE2 gel 
      Gel kept at ------ on -------. Reassessment at ------ 
      P/V during reassessment 
              cervix – Consistency 
              Position  
              Effacement   
              Membrane status 
              Station 
  Bishop score (after induction) 
 
2. Mifepristone  
    Drug given at --------- on -----------. 
Day 1 – NST – 
  FHR  
Day 2 – NST –  
  FHR 
Reassessment at ---------- on ------------ 
    P/V during reassessment 
               cervix – Consistency 
              Position  
              Effacement   
              Membrane status 
              Station 
Bishop score (after induction) 
   
 
Risk factors – low risk / high risk 
Duration of stages 
 I  
 II 
 III 
Mode of delivery 
Normal vaginal delivery + / - episiotomy 
Vaccum assisted vaginal delivery + /- episiotomy 
Forceps assisted vaginal delivery 
LSCS 
 
Baby details 
 APGAR – 1 min -  5 min –  
Resuscitation needed or not 
NICU admission needed or not 
Ventilatory support needed or not 
 
